Therefore, this prospective study, which reflects real-world practice, aimed to evaluate the 68Ga-PSMA-11 PET/TC diagnostic performance in the primary staging of patients with high-risk PCa compared to conventional imaging modalities, as well as to assess its potential impact on patient management. This evidence concerns the gene FOLH1 and posterior cortical atrophy.